Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Insider Monkey on MSN11d
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money, recently emphasized ...
Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback